Moa Pharmacology Iii Final

Front 1

Clavulanate MOA

Back 1

Suicide inhibitor for B-lactams
Re-routes acyl enzyme intermediate to inactivate B-lactamases

Front 2

Telithromycin MOA

Back 2

Ketolide that is resistant to methylation of A2058 in 23S rRNA (50S ribosome) due to alternate binding sites

Front 3

Fluconazole
type of anti-fungal
MOA
static or cidal?

Back 3

MOA: act on cell membrane by inhibiting ergosterol biosynthesis via inhibition of the CYP450 demethylase
-triazole
-fungicidal

Front 4

Terbinafine
type of anti-fungal
MOA
static or cidal?

Back 4

Allylamine act on cell membrane by inhibiting lanosterol (a precursor of ergosterol) to deplete ergosterol;
do this by inhibiting squalene epoxidase, resulting in high levels of squalene (fungistatic but cidal if you have enough)

Front 5

Amphotericin B
type of anti-fungal
MOA
resistance?

Back 5

polyene act on cell membrane by interacting with membrane sterols and ergosterol to form pores/channels that lead to leakage and cell death
- resistance is rare
- deposits into deep tissues and slowly releases

Front 6

Anidulafungin
type of anti-fungal
MOA
static or cidal?
resistance?
benefits to using this type of drug?

Back 6

Echinocandin noncompetitive inhibitor of B-glucan synthetase (a structural component of fungi cell wall)
fungicidal
resistance by target mutation
very low ADE, drug interactions,
no renal, no hepatic, no CYP interactions

Front 7

Valacyclovir
type of anti-viral
MOA

Back 7

Anti-HSV DNA pol inhibitor
substrate for intestinal peptide transporters

Front 8

Cidofovir
MOA
mimic of?

Back 8

Broad spectrum anti-DNA virus DNA pol inhibitor; acts as an alternate substrate of dCTP to terminate DNA elongation
- is a phosphonate mimic of cytidine

Front 9

Oseltamivir
MOA

Back 9

Anti-influenza virus neuraminidase inhibitor; neuraminidase cleaves off sialic acid from cell receptor so newly formed virions can be released (so interfere with virion release)

Front 10

Efavirenz
MOA

Back 10

Anti-HIV non-nucleoside RT inhibitor (NNRTI)
binds alternate site (not active site) in DNA pol and causes a conformational change in RT to inactivate it

Front 11

Tenofovir
MOA

Back 11

Anti-HIV nucleotide RT inhibitor (NtRTI)
has disoproxyl groups to enhance oral bioavailability

Front 12

Acyclovir
MOA

Back 12

Nucleoside analog (prodrug) must be converted to triphosphate to have activity
targets viral DNA polymerase by incorporating into DNA as a dead end

Front 13

Ritonavir
MOA

use in HIV therapy?

Back 13

HIV protease inhibitor prevents gag protein cleavage to structural and functional proteins

often used to boost therapeutic levels of protease inhibitors since it inhibits CYP3A4

Front 14

Saquinavir
MOA

Back 14

HIV protease inhibitor prevents gag protein cleavage to structural and functional proteins

Front 15

Peramivimir
MOA

Back 15

Anti-influenza virus neuraminidase inhibitor; neuraminidase cleaves off sialic acid from cell receptor so newly formed virions can be released (so interfere with virion release)

Front 16

Amantadine
MOA

Back 16

anti-influenza anti-viral
Blocks M2 channel (which is responsible for transporting H+ into virions and initiating uncoating process)